CG Oncology (CG Oncology) Cash And Cash Equivalents : $77.47 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Cash And Cash Equivalents?

CG Oncology's quarterly cash and cash equivalents declined from Sep. 2023 ($10.27 Mil) to Dec. 2023 ($8.27 Mil) but then increased from Dec. 2023 ($8.27 Mil) to Mar. 2024 ($77.47 Mil).

CG Oncology's annual cash and cash equivalents increased from Dec. 2021 ($53.61 Mil) to Dec. 2022 ($88.14 Mil) but then declined from Dec. 2022 ($88.14 Mil) to Dec. 2023 ($8.27 Mil).

CG Oncology Cash And Cash Equivalents Historical Data

The historical data trend for CG Oncology's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Cash And Cash Equivalents Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

53.61

88.14

8.27

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial			88.14	-	10.27	8.27	77.47

CG Oncology Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CG Oncology (NAS:CGON) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CG Oncology Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CG Oncology's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024